At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
rHuPH20 +1 moredrug
Likely dose
Placebo 0.25 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis
In Brief
A Phase 2 clinical trial evaluating rHuPH20 and Placebo for Dermatitis, Allergic Contact. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the prevention and treatment of skin allergic reaction to nickel. The study drug and placebo will be administered by intradermal injection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Allergic Contact
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJun 2009
Primary CompletionSep 2009
TodayJul 2026
First PostedJun 26, 2009
Enrollment StartJun 23, 2009
Primary CompletionSep 13, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.0 years ago
Interventions
rHuPH20drug
0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20
Placebodrug
0.25 mL ID syringe push bolus injection of placebo control